Related Experiment Videos
Anaphylaxis after treatment with recombinant factor VIII
R I Shopnick1, M Kazemi, D B Brettler
1Department of Hematology, New England Hemophilia Center, Medical Center of Central Massachusetts, Worcester, USA.
Transfusion
|April 1, 1996
Summary
Anaphylaxis after recombinant factor VIII (FVIII) concentrate is rare. This case study found no specific FVIII-related antigen or sterilant cause for the allergic reaction in a hemophilia A patient.
Area of Science:
- Hematology
- Immunology
- Allergy
Background:
- Recombinant factor VIII (FVIII) concentrates are standard hemophilia A treatment.
- Anaphylaxis is not a commonly reported adverse event associated with FVIII concentrates.
Observation:
- A 5-week-old boy with severe hemophilia A experienced anaphylaxis after receiving recombinant FVIII (Recombinate).
- Symptoms included dyspnea, cyanosis, hypotension, and urticarial rash.
Findings:
- Extensive testing revealed no antibodies to Recombinate-related antigens or ethylene oxide.
- Endotoxin was absent in the therapeutic product, ruling out pyrogenic reactions.
Implications:
- This case highlights a potential, albeit rare, risk of anaphylaxis with recombinant FVIII.
- Further investigation may be needed to understand the underlying mechanisms of such reactions.